Skip to main content

Table 1 Patient characteristics and previous chemotherapy

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Characteristic Number of patients (%)
Gender  
   Male 16 (62)
   Female 10 (38)
Age (years)  
   Mean (range) 58 (30-70)
ECOG Performance Status  
   0 8 (31)
   1 18 (69)
Tumour Type  
   Melanoma 8 (31)
   Colon, rectum or anus 3 (12)
   Non-small cell lung 3 (12)
   Sarcoma 3 (12)
   Glioblastoma 2 (8)
   Salivary gland 2 (8)
   Adrenal Cortex 1 (4)
   Cervix 1 (4)
   Head and neck 1 (4)
   Kidney 1 (4)
   Pancreas 1 (4)
Previous chemotherapy  
   No. of courses  
   None 4 (15)
   One 8 (31)
   Two 7 (27)
   Three 7 (27)